Duchenne Muscular Dystrophy
Duchenne Muscular Dystrophy
DOI:
https://doi.org/10.51473/rcmos.v1i1.2025.808Keywords:
Duchenne Muscular Dystrophy, Pathology, Dystrophin.Abstract
Duchenne muscular dystrophy (DMD) is a recessive X-linked disease, a progressive
and incurable disease that primarily affects the skeletal muscles. The dystrophin, a
structural protein that is related to stabilization of muscle contraction is absent or
altered in DMD. Patients with this dystrophy exhibit muscle wasting, impairing the
ability to run, jump and climb ladders, culminating in a confinement to a wheelchair, on
average 12 years old. Due to inactivity and immobility of the respiratory muscles, these
patients will die due to respiratory complications. Several therapeutic strategies have
been studied to improve the quality of life of these patients and their prognostics. The
present study consists of a literature review, covering the main aspects of pathology and
pointing out some of the different therapeutic strategies.
Downloads
References
Nussbaum RL. Thompson & Thompson: Genética Médica. 7.ed. Rio de
Janeiro: Guanabara-Koogan, 2008.
Sarlo LG, Silva AFA, Medina-Acosta E. Diagnóstico molecular da distrofia
muscular Duchenne. Revista Científica da FMC. 2009; 4(1): 02-09.
Yiu EM, Kornberg AJ. Duchenne muscular dystrophy. Neurol India. 2008;
: 236-47. DOI: 10.4103/0028-3886.43441
Giliberto F, Radic CP, Luce L, Ferreiro V, de Brasi C, Szijan I. Symptomatic
female carriers of Duchenne muscular dystrophy (DMD): Genetic and clinical
characterization. Journal of the neurological sciences. 2014; 336(1-2): 36-41. DOI:
1016/j.jns.2013.09.036
Constantin B. Dystrophin complex functions as a scaffold for signalling
proteins.
Biochimica et Biophysica Acta – Biomembranes. 2014; 1838(2): 635-42. DOI:
1016/j.bbamem.2013.08.023
Goldstein JA, McNally EM. Mechanisms of muscle weakness in muscular
dystrophy. The journal of general physiology. 2010; 136(1): 29. DOI:
1085/jgp.201010436
Darras BT, Miller DT, Urion DK. Dystrophinopathies. GeneReviews. 2014.
Liew WM, Kang PB. Recent developments in the treatment of Duchenne
muscular dystrophy and spinal muscular atrophy. Therapeutic Advances in
Neurological Disorders. 2013; 6(3): 147-60. DOI: 10.1177/1756285612472386
Moraes FM, Fernandes RCSC, Medina-Acosta E. Distrofia Muscular de
Duchenne: relato de caso. Revista Científica da FCM. 2011; 6(2): 11-15.
Porto CC. Semiologia médica. 7.ed. Rio de Janeiro: Guanabara Koogan,
Meier T, Rummey C, Leinonen M, Spagnola P, Mayer OH, Buyse GM.
Characterization of pulmonary function in 10–18 year old patients with Duchenne
muscular dystrophy. Neuromuscular Disorders Journal. 2017; 27(4): 307-14. DOI:
1016/j.nmd.2016.12.014
Thrush PT, Allen HD, Viollet L, Mendell JR. Re-examination of the
electrocardiogram in boys with Duchenne muscular dystrophy and correlation with its
dilated cardiomyopathy. Am. J. Cardiol. 2009; 103(2): 262-5. DOI:
1016/j.amjcard.2008.08.064
Takami Y, Takeshima Y, Awano H, Okizuka Y, Yagi M, Matsuo M. High
incidence of electrocardiogram abnormalities in young patients with Duchenne
muscular dystrophy. Pediatr Neurol. 2008; 39(6): 399-403. DOI:
1016/j.pediatrneurol.2008.08.006
Nardes F, Araújo AP, Ribeiro MG. Mental retardation in Duchenne muscular
dystrophy. Jornal de Pediatria (Rio de Janeiro). 2012; 88(1): 6-16. DOI:
2223/JPED.2148
Merrick D, Stadler LK, Larner D, Smith J. Muscular dystrophy begins early
in embryonic development deriving from stem cell loss and disrupted skeletal muscle
formation. Disease models and mechanisms. 2009; 2(7-8): 374-88.
DOI: 10.1242/dmm.001008
Lawler JM. Exacerbation of pathology by oxidative stress in respiratory and
locomotor muscles with Duchenne muscular dystrophy. The Journal of Physiology.
; 589(Pt 9): 2161-70. DOI: 10.1113/jphysiol.2011.207456
Ennen JP, Verma M, Asakura A. Vascular-targeted therapies for Duchenne
muscular dystrophy. Skeletal Muscle. 2013; 3(1): 9. DOI: 10.1186/2044-5040-3-9
Raboni TECR, Silva MFM, Pfeifer LI. Intervenção Terapêutica Ocupacional
junto à criança com Distrofia Muscular de Duchenne (DMD): um estudo de caso. Cad
Ter Ocup UFSCar. 2012; 20(1): 121-7. DOI: 10.4322/cto.2012.013
Masubuchi N, Shidoh Y, Kondo S, Takatoh J, Hanaoka K. Subcellular
Localization of Dystrophin Isoforms in Cardiomyocytes and Phenotypic Analysis of
Dystrophin-deficient Mice Reveal Cardiac Myopathy is Predominantly Caused by a
Deficiency in Full-length Dystrophin. Experimental animals. 2013; 62(3): 211-7.
DOI: 10.1538/expanim.62.211
Sienkiewicz D, Kulak W, Okurowska-Zawada B, Paszko-Patej G, Kawnik
K. Duchenne muscular dystrophy: current cell therapies. Therapeutic Advances in
Neurological Disorders. 2015; 8(4): 166-77. DOI: 10.1177/1756285615586123
Anderson JL, Head SI, Morley JM. Duchenne muscular dystrophy and brain
function. Intech. 2012; 5: 91-119. DOI: 10.5772/24928
Maranhão JB, Moreira DO, Maurício AF, Carvalho SC, Ferretti R, Pereira
JA, et al. Changes in calsequestrin, TNF-α, TGF-β and MyoD levels during the
progression of skeletal muscle dystrophy in mdx mice: a comparative analysis of the
quadriceps, diaphragm and intrinsic laryngeal muscles. International Journal of
Experimental Pathology. 2015; 96(5): 285-93. DOI: 10.1111/iep.12142
Ferretti R, Marques MJ, Khurana TS, Neto HS. Expression of calciumbuffering proteins in rat intrinsic laryngeal muscles. Physiological Reports. 2015; 3(6).
DOI: 10.14814/phy2.12409
Smythe GM. Dystrophic pathology in the intrinsic and extrinsic laryngeal
muscles in the mdx mouse. J. Otolaryngol Head Neck Surg. 2009; 38(3): 323-36.
Ferretti R, Neto HS, Marques MJ. Expression of Utrophin at DystrophinDeficient Neuromuscular Synapses of mdx Mice: A Study of Protected and Affected
Muscles. The Anathomical Record. 2010; 294(2): 283-6. DOI: 10.1002/ar.21297
Moat SJ, Bradley DM, Salmon R, Clarke A, Hartley L. Newborn bloodspot
screening for Duchenne Muscular Dystrophy: 21 years experience in Wales (UK).
European journal of human genetics. 2013; 21(10): 1049-53. DOI:
1038/ejhg.2012.301
Zhu Y, Zhang H, Sun Y, Li Y, Deng L, Wen X, et al. Serum Enzyme Profiles
Differentiate Five Types of Muscular Dystrophy. Disease Markers. 2015; 2015. DOI:
1155/2015/543282.
Bellayou H, Hamzi K, Rafai MA, Karkouri M, Slassi I, Azeddoug H, et al.
Duchenne and Becker muscular dystrophy: contribution of a molecular and
immunohistochemical analysis in diagnosis in Morocco. J Biomed Biotechnol. 2009;
: 325210. DOI: 10.1155/2009/325210
Na SJ, Kim WJ, Kim SM, Lee KO, Yoon B, Choi YC. Clinical
immunohistochemical, western blot, and genetic analysis in dystrophinopathy. Journal
of Clinical Neuroscience. 2013; 20(8): 1099-105. DOI: 10.1016/j.jocn.2012.09.021
Hegde MR, Chin EL, Mulle JG, Okou DT, Warren ST, Zwick ME.
Microarray-based mutation detection in the dystrophin gene. Hum mutat. 2008; 29(9):
-9. DOI: 10.1002/humu.20831
Yoo SK, Lim BC, Byeun J, Hwang H, Kim KJ, Hwang YS, et al.
Noninvasive prenatal diagnosis of duchenne muscular dystrophy: comprehensive
genetic diagnosis in carrier, proband, and fetus. Chin Chem. 2015; 61(6): 829-37. DOI:
1373/clinchem.2014.236380
McGreevy JW, Hakim CH, Mcintosh MA, Duan D. Animal models of
Duchenne muscular dystrophy: from basic mechanisms to gene therapy. Disease
Models and Mechanisms. 2015; 8(3): 195-213. DOI: 10.1242/dmm.018424
Fairclough RJ, Bareja A, Davies KE. Progress in therapy for Duchenne
muscular dystrophy. Exp Physiol. 2011; 96(11): 1101-13. DOI:
1113/expphysiol.2010.053025.
Grounds MD, Radley HG, Lynch GS, Nagaraju K, De Luca A. Towards
developing standard operating procedures for pre-clinical testing in the mdx mouse
model of Duchenne muscular dystrophy. Neurobiol Dis.2008; 31(1): 1-19. DOI:
1016/j.nbd.2008.03.008
Taniguti AP, Pertille A, Matsumura CY, Neto SH, Marques MJ. Prevention
of muscle fibrosis and myonecrosis in mdx mice by suramin, a TGF-beta1 blocker.
Muscle & nerve. 2011; 43(1): 82-7. DOI: 10.1002/mus.21869
Manning J, O’Malley D. What has the mdx mouse model of Duchenne
muscular dystrophy contributed to our understanding of this disease?. Journal of Muscle
Research and Cell Motility. 2015; 36(2): 155-67. DOI: 10.1007/s10974-015-9406-4
Zorzetto R, Guimarães M. Um peixe modelo: Mais prático e barato que os
roedores, o paulistinha começa a ser usado em pesquisas de neurociências e testes de
medicamentos no Brasil. Pesquisa Fapesp. 2013; 209.
Pichavant C, Aartsma-Rus A, Clemens PR, Davies KE, Dickson G, Takeda
S, et al. Current status of pharmaceutical and genetic therapeutic approaches to treat
Duchenne muscular dystrophy. Molecular Therapy. 2011; 19(5): 830-40.
DOI: 10.1038/mt.2011.59
Feder D, Macedo LP, Razaboni RS, Sabo HW, Sacardo KP. Duchenne
muscular dystrophy: a rewiew of corticosteroid bases treatment. Salud(i)Ciencia. 2010;
(5): 418-22.
Beytía ML, Vry J, Kirschner J. Drug treatment of Duchenne muscular
dystrophy: available evidence and perspectives. Acta Myologica. 2012; 31(1): 4-8.
Wong BL, Rybalsky I, Shellenbarger KC, Tian C, McMahon MA, Rutter
MM, et al. Long-Term Outcome of Interdisciplinary Management of Patients with
Duchenne Muscular Dystrophy Receiving Daily Glucocorticoid Treatment. The Journal
of Pediatrics. 2016; 182: 296-303. Doi: 10.1016/j.jpeds.2016.11.078
Malik V, Rodino-Klapac LR, Viollet L, Mendell JR. Aminoglycosideinduced mutation suppression (stop codon readthrough) as a therapeutic strategy for
Duchenne muscular dystrophy. Therapeutic Advances in Neurological Disorders. 2010;
(6): 379-89. DOI: 10.1177/1756285610388693
Selby NM, Shaw S, Woodier N, Fluck RJ, Kolhe NV. Gentamicin –
associated acute kidney injury. QJM. 2009; 102(12): 873-80. DOI:
1093/qjmed/hcp143
Rodrigues M, Echigoya Y, Fukada SI, Yokota T. Current Translational
Research and Murine Models For Duchenne Muscular Dystrophy. Journal of
Neuromuscular Diseases. 2016; 3(1): 29-48. DOI: 10.3233/JND-150113
Guiraud S, Squire SE, Edwards B, Chen H, Burns DT, Shah N, et al.
Second-generation compound for the modulation of utrophin in the therapy of DMD.
Human Molecular Genetics. 2015; 24(15): 4212-24. DOI: 10.1093/hmg/ddv154
Rodino-Klapac LR, Mendell JR, Sahenk Z. Update on the treatment of
Duchenne Muscular Dystrophy. Curr Neurol Neurosci Rep. 2013; 13(3): 332. DOI:
1007/s11910-012-0332-1
Muir LA, Chamberlain JS. Emerging strategies for cell and gene therapy of
the muscular dystrophies. Expert Rev Mol Med. 2009; 11: e18. DOI:
1017/S1462399409001100
Melo AP, Carvalho FA. Efeitos da fisioterapia respiratória na Distrofia
Muscular de Duchenne - Relato de Caso. Rev Neurocienc. 2011; 19(4): 686-93.
Fernandes NA, Troise DC, Fávero FM, Fontes SV, Oliveira ASB. A
Importância das Órteses de Membros Inferiores na Distrofia Muscular de Duchenne.
Rev Neurocienc. 2012; 20(4): 584-7. DOI: 10.4181/RNC.2012.20.701.4p
Zuo L, Pannell BK. Redox Characterization of Functioning Skeletal Muscle.
Frontiers in Physiology. 2015; 6: 338. DOI: 10.3389/fphys.2015.00338
Hyzewicz J, Ruegg UT, Takeda S. Comparison of Experimental Protocols of
Physical Exercise for mdx Mice and Duchenne Muscular Dystrophy Patients. Journal of
Neuromuscular Diseases. 2015; 2(4): 323-42. DOI: 10.3233/JND-150106
Jansen M, Groot IJM, Alfen N, Geurts ACH. Physical training in boys with
Duchenne Muscular Dystrophy: the protocol of the No Use is Disuse study. BMC
Pediatrics. 2010; 10: 55. DOI: 10.1186/1471-2431-10-55
Nakamura K, Kodama T, Mukaino Y. Effects of Active Individual Muscle
Stretching on Muscle Function. J Phys Ther Sci. 2014; 26(3) 341-4.
DOI: 10.1589/jpts.26.341
Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, et al.
Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of
multidisciplinary care. Lancet Neurol. 2010; 9(2): 177-89. DOI: 10.1016/S1474-
(09)70272-8
Downloads
Additional Files
Published
Issue
Section
License
Copyright (c) 2025 Candida Luiza Tonizza de Carvalho, Leslie Cristina Pinto Levy, Roberta Muniz Marques (Autor/in)
This work is licensed under a Creative Commons Attribution 4.0 International License.
This work is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This means you are free to:
- Share — copy and redistribute the material in any medium or format.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
The use of this material is conditioned upon proper attribution to the original author(s), providing a link to the license, and indicating if changes were made. The license does not require permission from the author or the publisher as long as these conditions are met.
The Creative Commons license logo is displayed permanently in the footer of the journal.
The copyright of the manuscript can be retained by the authors without restrictions and can be requested at any time, even after publication in the journal.
How to Cite
